CSIMarket
 


Mersana Therapeutics Inc   (MRSN)
Other Ticker:  
 

Cumulative Mersana Therapeutics Inc 's Long Term Debt to Equity for Trailing Twelve Months Period

MRSN's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

MRSN Long Term Debt to Equity for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth -59.91 % -42.15 % -33 % -54.25 % -24.38 %
Y / Y Long Term Debt Growth -7.14 % 1.22 % 1.22 % 1.22 % 1.23 %
Long Term Debt to Equity for Trailing Twelve Months Period 0.4 0.34 0.3 0.26 0.22
Total Ranking # 896 # 1178 # 1143 # 1107 # 1159
Seq. Equity Growth -29.3 % -41.88 % 39.67 % -30.16 % 2.03 %
Seq. Long Term Debt Growth -7.98 % 0.3 % 0.3 % 0.3 % 0.31 %


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite long-term debt repayement of -7.98% in IV. Quarter, Long Term Debt to Equity for Trailing Twelve Months Period improved to 0.4, a new company high.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 48 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Mersana Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is MRSN selling?
Long Term Debt to Equity MRSN in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 49
Sector # 133
S&P 500 # 1158


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.4 0.14 0.02
(Dec 31 2023)   (Mar 31 2021)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to Equity for Trailing Twelve Months Period
Tg Therapeutics Inc   1.06 
Spectrum Pharmaceuticals Inc   1.05 
Catalent Inc   1.04 
Tempest Therapeutics Inc   0.99 
Milestone Pharmaceuticals inc   0.88 
Axsome Therapeutics Inc   0.85 
Elanco Animal Health Inc  0.84 
Prestige Consumer Healthcare Inc   0.83 
Viatris Inc   0.83 
Perrigo Company Plc  0.82 
Cerevel Therapeutics Holdings Inc   0.82 
Mustang Bio inc   0.82 
Marinus Pharmaceuticals Inc   0.81 
Ani Pharmaceuticals Inc  0.77 
Vbi Vaccines Inc  0.76 
Innoviva Inc   0.76 
Avid Bioservices Inc   0.76 
Aptinyx Inc   0.73 
Cryoport inc   0.73 
Coya Therapeutics Inc   0.73 
Merck and Co Inc   0.72 
Pacira Biosciences inc   0.72 
Journey Medical Corporation  0.71 
Petros Pharmaceuticals inc   0.68 
Clene Inc   0.68 
Iterum Therapeutics Plc  0.66 
Verastem inc   0.65 
Pds Biotechnology Corp  0.64 
Royalty Pharma Plc  0.63 
Eyenovia inc   0.62 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com